Company news

Neurotech International Ltd. news in 2026

Neurotech International Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Final Director's Interest Notice

November 5, 2026

Results of Meeting

November 4, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Ceasing to be a substantial holder

October 19, 2026

Corporate Presentation

October 19, 2026

Becoming a substantial holder

October 19, 2026

Change of Director's Interest Notice

October 6, 2026

Annual Report (Typeset)

October 5, 2026

Notice of Annual General Meeting/Proxy Form

October 1, 2026

NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study

September 20, 2026

Initial Director's Interest Notice

September 8, 2026

Notification of cessation of securities - NTI

September 8, 2026

Board and Management Changes

September 7, 2026

Final Director's Interest Notice

September 7, 2026

Appendix 4G and Corporate Governance Statement

August 26, 2026

Appendix 4E & Annual Report to shareholders

August 26, 2026

Appointment of Executive Chairman

August 16, 2026

Becoming a substantial holder

August 12, 2026

Secondary Trading Notice

August 11, 2026

Application for quotation of securities - NTI

August 11, 2026

Receipt of Binding Commitments for $4.5m Placement

August 3, 2026

Proposed issue of securities - NTI

August 3, 2026

Proposed issue of securities - NTI

August 3, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 30, 2026

Trading Halt

July 30, 2026

NTI164 Phase II/III Autism Data Accepted for Publication

July 29, 2026

Neurotech secures $3.15 million R&D tax incentive loan

July 14, 2026

US FDA clears IND for NTI164

July 13, 2026

NTI secures Notices of Allowance for US patent applications

July 1, 2026

NTI initiates First Clinical Site for Phase 3 ASD Trial

March 16, 2026

Appendix 4D & Half Year Report

February 26, 2026

Positive 90-day GLP toxicology study results in non-rodents

February 22, 2026

Approval received for NTI164 Phase 3 Clinical Study in ASD

February 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Decks in 2026